Corvus Pharmaceuticals (CRVS) Stock Chart & Stock Price History → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free CRVS Stock Alerts $1.51 -0.02 (-1.31%) (As of 04/24/2024 ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Corvus Pharmaceuticals Stock Price Performance5 Day Performance+9.29%1 Month Performance-14.53%3 Month Performance-24.63%6 Month Performance+29.66%Year-To-Date Performance-13.07%1 Year Performance+53.00% Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> CRVS Stock Chart for Wednesday, April, 24, 2024 CRVS Chart by TradingView Corvus Pharmaceuticals Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization04/23/2024$1.44$1.53+6.25%$1.57$1.43137,350 shs$75.03 million04/22/2024$1.40$1.44+2.86%$1.50$1.39130,628 shs$70.62 million04/19/2024$1.41$1.40-0.71%$1.44$1.3658,794 shs$68.66 million04/18/2024$1.36$1.41+3.68%$1.45$1.30140,408 shs$69.15 million04/17/2024$1.47$1.36-7.48%$1.51$1.36112,505 shs$66.69 million04/16/2024$1.47$1.47$1.51$1.3691,610 shs$72.09 million Get the Latest News and Ratings for CRVS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 04/15/2024$1.53$1.47-3.92%$1.54$1.4168,232 shs$72.09 million04/12/2024$1.56$1.53-1.92%$1.62$1.50155,079 shs$75.03 million04/11/2024$1.51$1.56+3.31%$1.61$1.52122,703 shs$76.50 million04/10/2024$1.63$1.51-7.36%$1.67$1.46228,263 shs$74.05 million04/09/2024$1.71$1.63-4.68%$1.78$1.60196,126 shs$79.94 million04/08/2024$1.75$1.71-2.29%$1.79$1.68120,408 shs$83.86 million04/05/2024$1.69$1.75+3.55%$1.78$1.63189,988 shs$85.82 million04/04/2024$1.75$1.69-3.43%$1.85$1.69211,054 shs$82.88 million04/03/2024$1.86$1.75-5.91%$1.86$1.73490,276 shs$85.82 million04/02/2024$1.86$1.86$1.94$1.78121,773 shs$91.21 million04/01/2024$1.78$1.86+4.49%$1.89$1.74117,243 shs$91.21 million03/29/2024$1.78$1.78$1.85$1.76273,600 shs$87.29 million03/28/2024$1.79$1.78-0.56%$1.85$1.76273,600 shs$87.29 million03/27/2024$1.76$1.79+1.70%$1.85$1.76160,298 shs$87.78 million03/26/2024$1.76$1.76$1.87$1.76302,463 shs$86.31 million03/25/2024$1.79$1.76-1.68%$1.84$1.72277,923 shs$86.31 million03/22/2024$1.84$1.79-2.72%$1.88$1.72323,851 shs$87.78 million03/21/2024$1.85$1.84-0.54%$1.95$1.79274,495 shs$90.23 million03/20/2024$1.96$1.85-5.61%$1.98$1.82277,665 shs$90.72 million03/19/2024$1.90$1.96+3.16%$2.00$1.91205,146 shs$96.12 million03/18/2024$1.90$1.90$2.00$1.90163,443 shs$93.18 million03/15/2024$1.88$1.90+1.06%$1.99$1.88172,988 shs$93.17 million03/14/2024$2.00$1.88-6.00%$2.01$1.81264,676 shs$92.20 million03/13/2024$2.02$2.00-0.99%$2.08$2.0088,608 shs$98.08 million03/12/2024$2.01$2.02+0.50%$2.10$1.86228,797 shs$99.06 million03/11/2024$2.12$2.01-5.19%$2.19$1.97272,706 shs$98.57 million03/08/2024$2.28$2.12-7.02%$2.34$2.11245,889 shs$103.97 million03/07/2024$2.15$2.28+6.05%$2.34$2.09214,951 shs$111.81 million03/06/2024$2.11$2.15+1.90%$2.19$2.08197,805 shs$105.43 million03/05/2024$2.16$2.11-2.31%$2.20$2.02163,300 shs$103.47 million03/04/2024$2.18$2.16-0.92%$2.30$2.14275,489 shs$105.93 million03/01/2024$2.24$2.18-2.68%$2.28$2.15328,202 shs$106.91 million02/29/2024$2.30$2.24-2.61%$2.39$2.21211,809 shs$109.85 million02/28/2024$2.36$2.30-2.54%$2.40$2.25290,288 shs$112.79 millionPentagon contract could send this $2 AI stock soaring (Ad)Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>>02/27/2024$2.30$2.36+2.61%$2.45$2.28413,469 shs$115.73 million02/26/2024$2.35$2.30-2.13%$2.38$2.27151,131 shs$112.79 million02/23/2024$2.31$2.35+1.73%$2.41$2.29105,488 shs$115.24 million02/22/2024$2.30$2.31+0.43%$2.40$2.2899,444 shs$113.28 million02/21/2024$2.32$2.30-0.86%$2.33$2.2466,176 shs$112.79 million02/20/2024$2.29$2.32+1.31%$2.43$2.21202,815 shs$113.77 million02/19/2024$2.29$2.29$2.34$2.22206,700 shs$112.30 million02/16/2024$2.35$2.29-2.55%$2.34$2.22206,713 shs$112.30 million02/15/2024$2.23$2.35+5.38%$2.35$2.12310,935 shs$115.24 million02/14/2024$2.23$2.23$2.29$2.18141,638 shs$109.36 million02/13/2024$2.27$2.23-1.76%$2.33$2.17194,876 shs$109.36 million02/12/2024$2.22$2.27+2.48%$2.34$2.19296,387 shs$111.32 million02/09/2024$2.00$2.22+10.75%$2.58$2.081.03 million shs$108.62 million02/08/2024$2.07$2.00-3.38%$2.07$1.96168,177 shs$98.08 million02/07/2024$2.04$2.07+1.47%$2.10$1.99134,737 shs$101.51 million02/06/2024$2.01$2.04+1.49%$2.05$1.95131,708 shs$100.04 million02/05/2024$2.10$2.01-4.29%$2.10$1.94107,075 shs$98.57 million02/02/2024$2.13$2.10-1.41%$2.13$2.0347,492 shs$102.98 million02/01/2024$2.00$2.13+6.50%$2.15$2.0056,657 shs$98.08 million01/31/2024$2.08$2.00-3.85%$2.16$2.0049,085 shs$98.08 million01/30/2024$2.14$2.08-2.80%$2.22$2.0794,785 shs$102.00 million01/29/2024$2.05$2.14+4.39%$2.15$1.9971,461 shs$104.95 million01/26/2024$2.05$2.05$2.10$2.0072,902 shs$100.53 million01/25/2024$2.03$2.05+0.99%$2.09$1.9977,724 shs$100.53 million01/24/2024$2.04$2.03-0.49%$2.10$2.0169,809 shs$99.55 million01/23/2024$2.05$2.04-0.49%$2.13$1.98170,252 shs$100.04 million Related Companies: Cue Biopharma Stock Price Chart Carisma Therapeutics Stock Price Chart MediciNova Stock Price Chart Tempest Therapeutics Stock Price Chart Assertio Stock Price Chart Journey Medical Stock Price Chart Anebulo Pharmaceuticals Stock Price Chart Rallybio Stock Price Chart Leap Therapeutics Stock Price Chart Immix Biopharma Stock Price Chart Receive CRVS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:CRVS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.